RET and medullary thyroid gland carcinoma: Since then, RET solvent front mutations have been reported in many other RET-altered NSCLC and MTC treated with either selpercatinib or pralsetinib, accounting for around 20–25% cases of acquired resistance (Lin et al. 2020, Subbiah et al. 2021a, Gainor et al. 2021b, Rosen et al. 2022, Hadoux et al. 2023b) (Fig. 3) (Supplementary Table).